Two high-profile downgrades landed this week. Analysts cut their ratings on both JCI and BMY, the latest signs of caution in industrials and biopharma.
Johnson Controls took a downgrade from a Buy-equivalent to Hold. The target price slipped to $162.05 from $161.05. The building technology giant carries a market cap near $89 billion. Its SI % FF sits at just 1.6%, so short sellers are not yet piling in.
Bristol-Myers Squibb also received a downgrade. The consensus balance shifted, with one fewer Hold rating and one more Sell. The average target fell to $64.91. BMY trades near $133 billion in market cap. Short interest remains modest at 2.4% of float.
On the positive side, AMZN continues to attract upgrades. Target prices edged up to $321.95 on average. Consensus is overwhelmingly bullish with 59 Buy ratings and just three Holds.
RCL picked up a new analyst recommendation. The cruise operator saw its average target reach $349.73. With 16 Buy ratings, Wall Street remains upbeat on leisure travel demand.
ABBV and CTVA also saw target price increases this week, reflecting steady optimism in pharma and agriculture.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
